Emcure Pharmaceuticals delivered a strong performance in the March quarter, led by robust growth in its international business and steady improvement in margins.
For Q4 FY26, the company reported revenue from operations of ₹2,470 crore, registering a 16.7% year-on-year increase. EBITDA rose sharply by 24.5% YoY to ₹485 crore, with EBITDA margins improving to 19.7% compared to 18.4% in the same quarter last year.
Profitability also saw a healthy uptick, with reported profit after tax (PAT) rising 23.6% YoY to ₹244 crore, while adjusted PAT stood at ₹279 crore, up 36% YoY.
The company’s international business remained a key growth driver during the quarter, with revenues rising 25.7% YoY to ₹1,493 crore, supported by strong performance across markets, base business ramp-up, and new product launches. In contrast, domestic business growth was relatively muted, with revenues increasing 5.2% YoY to ₹977 crore, impacted by portfolio adjustments and organisational changes.
Commenting on the performance, Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, said, “In FY26, the first year of our five-year strategic plan, Emcure delivered strong financial performance with over US$1 billion in revenue and 16.6% growth. International markets demonstrated robust momentum while our domestic business recorded steady growth. We delivered ~41% adjusted PAT growth in the year. Our R&D pipeline in complex injectables and biosimilars remains a key driver of future value, and we remain focused on sustainable, above-industry growth and consistent margin expansion.”
On a full-year basis, Emcure reported revenue of ₹9,204 crore for FY26, marking a 16.6% YoY growth. EBITDA for the year stood at ₹1,789 crore, up 21.8% YoY, with margins at 19.4%. Reported PAT came in at ₹941 crore, rising 33.1% YoY, while adjusted PAT stood at ₹1,008 crore, up 40.9% YoY.
The domestic business recorded sales of ₹4,027 crore for FY26, growing 10% YoY, driven by key therapeutic areas such as cardiac, CNS, and oncology. Meanwhile, the international segment delivered strong growth of 22.2% YoY, with revenues at ₹5,177 crore, supported by expansion in key markets and new product introductions.
Overall, Emcure’s Q4 performance underscores strong execution in international markets and improving profitability, while the company continues to invest in its pipeline and long-term growth strategy.